menu
    • menu
    [{"orgOrder":0,"company":"Unum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ACTR707","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Unum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Unum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Unum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BOXR1030","moa":"T-cell receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Unum Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Unum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Unum Therapeutics","sponsor":"Sotio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"BOXR1030","moa":"T-cell receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Unum Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unum Therapeutics \/ Sotio","highestDevelopmentStatusID":"4","companyTruncated":"Unum Therapeutics \/ Sotio"}]

    Find Clinical Drug Pipeline Developments & Deals by Unum Therapeutics

    Menu

    Unum Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Unum Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Unum Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BOXR1030

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Sotio

                            Deal Size : $11.5 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            SOTIO Acquires Rights to BOXR CAR-T Platform and Products from Unum Therapeutics

                            Details : SOTIO has acquired the rights to Unum Therapeutics’ BOXR cell therapy platform and BOXR lead programs to develop novel T cell therapies for the treatment of solid tumors.

                            Product Name : BOXR1030

                            Product Type : Cell and Gene therapy

                            Upfront Cash : $8.1 million

                            August 31, 2020

                            Lead Product(s) : BOXR1030

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Sotio

                            Deal Size : $11.5 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Unum Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Unum Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BOXR1030

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Unum Implements Strategic Restructuring to Prioritize Efforts on BOXR1030

                            Details : Unum has initiated formal preclinical development activities, including preclinical safety testing and GMP process development, to support filing an IND application for BOXR1030 in late 2020.

                            Product Name : BOXR1030

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 03, 2020

                            Lead Product(s) : BOXR1030

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Unum Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Unum Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ACTR707,Trastuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Unum Therapeutics Provides Updates to its Phase 1 Trial of ACTR707 for HER2+ Solid Tumor Cancers

                            Details : Cohort 1 recruitment is complete with no dose-limiting toxicity reported in the ATTCK-34-01 Phase 1 trial testing Unum's novel ACTR707 antibody-coupled T cell receptor investigational therapy with trastuzumab.

                            Product Name : ACTR707

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            January 29, 2020

                            Lead Product(s) : ACTR707,Trastuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth